CTLA4 and melanoma: Additionally, Wolchok et al. reported from a phase III study of PD-1 and CTLA-4 blockade in melanoma that PD-L1 appeared to be prognostic of improved overall survival rather than predictive of checkpoint blockade therapeutic response (232).